Kenya is one of nine African countries selected for the initial rollout of lenacapavir (LEN), a new injectable drug for human ...

Gilead Sciences, Inc. (NASDAQ:GILD) is among the 11 Best GLP-1 and Weight Loss Stocks to Invest in. Gilead Sciences, Inc.

Lenacapavir’s capsid inhibition is relatively less understood compared to mechanisms of other approved approaches in HIV. However, the capsid protein is essential for viral entry and hence ...

Recent developments in antiretroviral therapy (ART) include longer-acting therapies that don't require a daily oral pill and ...

Lenacapavir, an antiretroviral drug typically used to treat HIV infections, can also effectively prevent them, a phase 3 clinical trial has shown.

Lenacapavir is given in two injections that have to be delivered subcutaneously, something that “takes training and time” to learn, National Institute of Allergy and Infectious Diseases ...

“Lenacapavir represents a major scientific advance — it’s the first long-acting injectable HIV prevention strategy that requires dosing just twice a year,” according to Paul E. Sax, MD ...

The European Union's drugs regulator has recommended approval of Gilead Sciences' lenacapavir, a twice-yearly injection, for ...

Lenacapavir, a long-acting HIV capsid inhibitor that could potentially be given every six months, continues to show good viral suppression, both in people starting antiretroviral therapy for the first ...

LONDON (AP) — The European Medicines Agency has recommended authorizing a twice-yearly injectable drug aimed at preventing HIV, which scientists say could help end the virus’ transmission.

Lenacapavir binds to the conical capsid that encapsulates the HIV viral genome. If successful in larger phase 3 trials, it would be the first capsid inhibitor in HIV to come to market.

Lenacapavir’s cost as HIV treatment in the United States in 2023 was $42,250 per new patient per year. Oral PrEP options, on the other hand, can cost less than $4 a month.